Head to Head Stocks: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Douglas Emmett, Inc. (NYSE:DEI)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed at $112.49 on the last trading session with an decrease of -4.71%, whereas, it previously closed at $118.05. The company has a market capitalization of $12.87 Billion. The company traded shares of 925725 on the trading day while its three month average volume stands at 665.67 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) produced diluted EPS of -8.14. The EPS estimate for next year as estimated by analysts is at -4.74 while EPS for next quarter is estimated at -1.88. Earnings per Share growth for this year is reported at -7, while the analysts estimated the EPS growth for next year at -4.74% and Earnings growth for next 5 years stands at 46.09% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -10.8%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands at 58.54 and Price to Book or P/B for the most recent quarter stands at 8.74. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) are reported at 4.7 and 4.9 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands at -36.7, -55.8 and -65.4 respectively

The trailing twelve month Revenue of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is reported at 219.8 Million with income of -886100000. The outstanding shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) are 114.38 Million. The institutional Ownership of the shares of 95.7 stands at 0.80%, this figure is decreased -1.86 in the last six months. The insider ownership for the shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is ticked at 0.5%, the figure is plummeted -41.08% in the last six months.

Some other important financial aspects to be discussed here for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is the Mean Target Price estimated by the analysts which stands at 138.63. The 52 week high of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is placed at 134.51 and 52 week low is standing at 65.81.

Performance wise the shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) fell down -15.5% for the week, it also fell -1.94% for the monthly performance, while for the quarter it went down 0.06%. The shares increase 36.83% for the half year and plummeted for the Year-To-Date performance. The shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) grew 32.34% for the yearly performance.

Douglas Emmett, Inc. (NYSE:DEI)

Douglas Emmett, Inc. (NYSE:DEI) closed at $39.19 on the last trading session with an decrease of -5.63%, whereas, it previously closed at $41.53. The company has a market capitalization of $6.93 Billion. The company traded shares of 848357 on the trading day while its three month average volume stands at 1.13 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Douglas Emmett, Inc. (NYSE:DEI) produced diluted EPS of 2.07. The EPS estimate for next year as estimated by analysts is at 0.8 while EPS for next quarter is estimated at 0.16. Earnings per Share growth for this year is reported at 207.2, while the analysts estimated the EPS growth for next year at 0.8% and Earnings growth for next 5 years stands at 8% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 47.3%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Douglas Emmett, Inc. (NYSE:DEI) is at 18.9 while the forward p/e is at 48.99. The P/S or Price to Sales ratio of Douglas Emmett, Inc. (NYSE:DEI) stands at 7.39 and Price to Book or P/B for the most recent quarter stands at 2.53. The Price to Free Cash Flow ratio or P/FCF is reported at 30.35. The quick ratio and the current ratio of Douglas Emmett, Inc. (NYSE:DEI) are reported at 0 and 0 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Douglas Emmett, Inc. (NYSE:DEI) stands at 4.2, 14.5 and 3.4 respectively

The trailing twelve month Revenue of Douglas Emmett, Inc. (NYSE:DEI) is reported at 936.7 Million with income of 362.1 Million. The outstanding shares of Douglas Emmett, Inc. (NYSE:DEI) are 176.71 Million. The institutional Ownership of the shares of 95.9 stands at 0.80%, this figure is increased 0.16 in the last six months. The insider ownership for the shares of Douglas Emmett, Inc. (NYSE:DEI) is ticked at 2%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Douglas Emmett, Inc. (NYSE:DEI) is the Mean Target Price estimated by the analysts which stands at 45.67. The 52 week high of Douglas Emmett, Inc. (NYSE:DEI) is placed at 45.59 and 52 week low is standing at 38.13.

Performance wise the shares of Douglas Emmett, Inc. (NYSE:DEI) fell down -12.64% for the week, it also fell -5.09% for the monthly performance, while for the quarter it went up -10.36%. The shares decrease -4.92% for the half year and plummeted for the Year-To-Date performance. The shares of Douglas Emmett, Inc. (NYSE:DEI) grew 1.63% for the yearly performance.